Self-Nanoemulsion Intrigues the Gold Phytopharmaceutical Chrysin : In Vitro Assessment and Intrinsic Analgesic Effect
© 2024. The Author(s)..
Chrysin is a natural flavonoid with a wide range of bioactivities. Only a few investigations have assessed the analgesic activity of chrysin. The lipophilicity of chrysin reduces its aqueous solubility and bioavailability. Hence, self-nanoemulsifying drug delivery systems (SNEDDS) were designed to overcome this problem. Kollisolv GTA, Tween 80, and Transcutol HP were selected as oil, surfactant, and cosurfactant, respectively. SNEDDS A, B, and C were prepared, loaded with chrysin (0.1%w/w), and extensively evaluated. The optimized formula (B) encompasses 25% Kollisolv GTA, 18.75% Tween 80, and 56.25% Transcutol HP was further assessed. TEM, in vitro release, and biocompatibility towards the normal oral epithelial cell line (OEC) were estimated. Brain targeting and acetic acid-induced writhing in a mouse model were studied. After testing several adsorbents, powdered SNEDDS B was formulated and evaluated. The surfactant/cosurfactant (S/CoS) ratio of 1:3 w/w was appropriate for the preparation of SNEDDS. Formula B exhibited instant self-emulsification, spherical nanoscaled droplets of 155.4 ± 32.02 nm, and a zeta potential of - 12.5 ± 3.40 mV. The in vitro release proved the superiority of formula B over chrysin suspension (56.16 ± 10.23 and 9.26 ± 1.67%, respectively). The biocompatibility of formula B towards OEC was duplicated (5.69 ± 0.03 µg/mL). The nociceptive pain was mitigated by formula B more efficiently than chrysin suspension as the writhing numbers reduced from 8.33 ± 0.96 to 0 after 60 min of oral administration. Aerosil R972 was selected as an adsorbent, and its chemical compatibility was confirmed. In conclusion, our findings prove the therapeutic efficacy of chrysin self-nanoemulsion as a potential targeting platform to combat pain.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 25(2024), 3 vom: 05. März, Seite 54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elhoseny, Samar Mohamed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3CN01F5ZJ5 |
|---|
| Anmerkungen: |
Date Completed 07.03.2024 Date Revised 26.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1208/s12249-024-02767-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369334892 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369334892 | ||
| 003 | DE-627 | ||
| 005 | 20240326235713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-024-02767-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM369334892 | ||
| 035 | |a (NLM)38443653 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elhoseny, Samar Mohamed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Self-Nanoemulsion Intrigues the Gold Phytopharmaceutical Chrysin |b In Vitro Assessment and Intrinsic Analgesic Effect |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Chrysin is a natural flavonoid with a wide range of bioactivities. Only a few investigations have assessed the analgesic activity of chrysin. The lipophilicity of chrysin reduces its aqueous solubility and bioavailability. Hence, self-nanoemulsifying drug delivery systems (SNEDDS) were designed to overcome this problem. Kollisolv GTA, Tween 80, and Transcutol HP were selected as oil, surfactant, and cosurfactant, respectively. SNEDDS A, B, and C were prepared, loaded with chrysin (0.1%w/w), and extensively evaluated. The optimized formula (B) encompasses 25% Kollisolv GTA, 18.75% Tween 80, and 56.25% Transcutol HP was further assessed. TEM, in vitro release, and biocompatibility towards the normal oral epithelial cell line (OEC) were estimated. Brain targeting and acetic acid-induced writhing in a mouse model were studied. After testing several adsorbents, powdered SNEDDS B was formulated and evaluated. The surfactant/cosurfactant (S/CoS) ratio of 1:3 w/w was appropriate for the preparation of SNEDDS. Formula B exhibited instant self-emulsification, spherical nanoscaled droplets of 155.4 ± 32.02 nm, and a zeta potential of - 12.5 ± 3.40 mV. The in vitro release proved the superiority of formula B over chrysin suspension (56.16 ± 10.23 and 9.26 ± 1.67%, respectively). The biocompatibility of formula B towards OEC was duplicated (5.69 ± 0.03 µg/mL). The nociceptive pain was mitigated by formula B more efficiently than chrysin suspension as the writhing numbers reduced from 8.33 ± 0.96 to 0 after 60 min of oral administration. Aerosil R972 was selected as an adsorbent, and its chemical compatibility was confirmed. In conclusion, our findings prove the therapeutic efficacy of chrysin self-nanoemulsion as a potential targeting platform to combat pain | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a aerosil R972 | |
| 650 | 4 | |a analgesic | |
| 650 | 4 | |a chrysin | |
| 650 | 4 | |a self-nanoemulsifying system | |
| 650 | 4 | |a writhing | |
| 650 | 7 | |a carbitol |2 NLM | |
| 650 | 7 | |a A1A1I8X02B |2 NLM | |
| 650 | 7 | |a chrysin |2 NLM | |
| 650 | 7 | |a 3CN01F5ZJ5 |2 NLM | |
| 650 | 7 | |a Polysorbates |2 NLM | |
| 650 | 7 | |a Flavonoids |2 NLM | |
| 650 | 7 | |a Surface-Active Agents |2 NLM | |
| 650 | 7 | |a Gold |2 NLM | |
| 650 | 7 | |a 7440-57-5 |2 NLM | |
| 650 | 7 | |a Ethylene Glycols |2 NLM | |
| 700 | 1 | |a Saleh, Noha Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Meshali, Mahasen Mohamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d 2000 |g 25(2024), 3 vom: 05. März, Seite 54 |w (DE-627)NLM126699429 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:05 |g month:03 |g pages:54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1208/s12249-024-02767-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 3 |b 05 |c 03 |h 54 | ||